Last updated on January 2020

Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment


Brief description of study

The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo. In addition, an open-label, delayed-start phase is included to demonstrate a disease-modifying effect of TRx0237.

Clinical Study Identifier: NCT03446001

Find a site near you

Start Over

The Roskamp Institute, Inc.

Sarasota, FL United States
3.67miles
  Connect »